Rydar Equities’s Vertex Pharmaceuticals VRTX Stock Holding History

Rydar Equities’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$10.1K	Buy	+20	New	+$10.2K	0.01%	301

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return

IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

Rydar Equities's VRTX Position: Q3 2026 in Review

Rydar Equities opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2026: 20 shares worth $10.1K. The stake represents 0.01% of the portfolio and ranks #301 among its holdings.

323 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Rydar Equities held 20 shares of Vertex Pharmaceuticals worth $10.1K as of Q3 2026.
Vertex Pharmaceuticals was a new Rydar Equities position in Q3 2026.
Vertex Pharmaceuticals made up 0.01% of Rydar Equities's portfolio in Q3 2026, its #301 holding.
323 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Rydar Equities's 13F filing for Q3 2026, filed 13 Oct 2026.